Guillain–Barré Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks part of its peripheral nervous system—the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with a brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently. Most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness. There are several types of Guillain–Barré syndrome, classified by the part of the peripheral nerve involved in the condition. The most common type of Guillain–Barré syndrome are:
o Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
o Miller Fisher syndrome
o Acute Motor Axonal Neuropathy (AMAN) and Acute Motor‐sensory Axonal Neuropathy
Visit For Sample Pages:
The Guillain-Barre Syndrome market report aslo covers emerging drugs, current treatment practices, Guillain-Barre Syndrome market share of the individual therapies, current and forecasted Guillain-Barre Syndrome Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Guillain-Barre Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Guillain-Barre Syndrome Market Key Facts
As per the study conducted by Yoshikawa, males were affected 1.5 times more frequently than females.
As per the study conducted by Walling et al. (2013), the estimated overall annual incidence of GBS in the US is 1.65–1.79 per 100,000 persons.
As per the “National Institute of Health,” the Incidence of Guillain–Barré Syndrome is estimated to be 6–40 cases per 1 million people.
As per the “National Institute of Health”, AMAN and AMSAN together account for 30–50 % of cases in Asian countries and Latin America but only 3–5 % of cases in North America and Europe.
Another study titled “Incidence of Guillain–Barré Syndrome in Germany “, by Lehmann et al. (2008), the estimated incidence rates of GBS in Germany between 2003 and 2005 ranged from 1.6 to 1.89 per 100,000, with a mean incidence rate of 1.75 per 100,000.
Key Benefits of Guillain-Barre Syndrome Market Report
Guillain-Barre Syndrome market report provides an in-depth analysis of Guillain-Barre Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Guillain-Barre Syndrome market report will help in developing business strategies by understanding the Guillain-Barre Syndrome Market trends & developments, key players and future market competition that will shape and drive the Guillain-Barre Syndrome market in the upcoming years.
The Guillain-Barre Syndrome market report covers Guillain-Barre Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Guillain-Barre Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Guillain-Barre Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Guillain-Barre Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Guillain-Barre Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Guillain–Barré Syndrome (GBS) is a clinically heterogeneous spectrum of rare post‐infectious neuropathies whose exact cause is not known. Researchers do not know why it affects some people and not others. It is not contagious or inherited. Since the body’s own immune system does the damage, GBS is called an autoimmune disease. In rare cases, vaccinations may increase the risk of GBS. Recently, some countries worldwide reported an increased incidence of GBS following infection with the Zika virus.
The Guillain-Barre Syndrome epidemiology section covers insights about historical and current Guillain-Barre Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Guillain-Barre Syndrome Drugs Uptake and Key Market Players
The Guillain-Barre Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Guillain-Barre Syndrome market or expected to get launched in the market during the study period. The analysis covers Guillain-Barre Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Table of Content
1. Key Insights
2. Executive Summary
3. Guillain-Barre Syndrome Competitive Intelligence Analysis
4. Guillain-Barre Syndrome Market Overview at a Glance
5. Guillain-Barre Syndrome Disease Background and Overview
6. Guillain-Barre Syndrome Patient Journey
7. Guillain-Barre Syndrome Epidemiology and Patient Population
8. Guillain-Barre Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Guillain-Barre Syndrome Unmet Needs
10. Key Endpoints of Guillain-Barre Syndrome Treatment
11. Guillain-Barre Syndrome Marketed Products
12. Guillain-Barre Syndrome Emerging Therapies
13. Guillain-Barre Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Guillain-Barre Syndrome Market Outlook (7 major markets)
16. Guillain-Barre Syndrome Access and Reimbursement Overview
17. KOL Views on the Guillain-Barre Syndrome Market.
18. Guillain-Barre Syndrome Market Drivers
19. Guillain-Barre Syndrome Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
DelveInsight’s Guillain-Barre Syndrome (GBS) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Guillain-Barre Syndrome (GBS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Guillain-Barre Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Guillain-Barre Syndrome market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States